EP4323407A1 - Zusammensetzungen und verfahren zur behandlung von chronischen aktiven läsionen von weissem material / radiologisch isoliertem syndrom - Google Patents
Zusammensetzungen und verfahren zur behandlung von chronischen aktiven läsionen von weissem material / radiologisch isoliertem syndromInfo
- Publication number
- EP4323407A1 EP4323407A1 EP22726324.1A EP22726324A EP4323407A1 EP 4323407 A1 EP4323407 A1 EP 4323407A1 EP 22726324 A EP22726324 A EP 22726324A EP 4323407 A1 EP4323407 A1 EP 4323407A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- sel
- patient
- sels
- natalizumab
- lesions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 66
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 10
- 230000001684 chronic effect Effects 0.000 title claims description 135
- 206010072731 White matter lesion Diseases 0.000 title claims description 27
- 239000000203 mixture Substances 0.000 title description 3
- 230000003902 lesion Effects 0.000 claims abstract description 240
- 201000010099 disease Diseases 0.000 claims abstract description 48
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 48
- 238000009175 antibody therapy Methods 0.000 claims abstract description 31
- 230000008045 co-localization Effects 0.000 claims abstract description 13
- 230000005291 magnetic effect Effects 0.000 claims abstract description 7
- 229960005027 natalizumab Drugs 0.000 claims description 102
- 238000011282 treatment Methods 0.000 claims description 46
- 230000000694 effects Effects 0.000 claims description 39
- 230000001154 acute effect Effects 0.000 claims description 34
- 238000007920 subcutaneous administration Methods 0.000 claims description 31
- 238000010801 machine learning Methods 0.000 claims description 30
- 230000002051 biphasic effect Effects 0.000 claims description 27
- 230000006698 induction Effects 0.000 claims description 24
- 229950005751 ocrelizumab Drugs 0.000 claims description 10
- 230000000977 initiatory effect Effects 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 abstract description 82
- 230000005298 paramagnetic effect Effects 0.000 abstract description 7
- 238000002595 magnetic resonance imaging Methods 0.000 description 89
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 description 61
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 57
- 210000004556 brain Anatomy 0.000 description 35
- 239000000902 placebo Substances 0.000 description 34
- 229940068196 placebo Drugs 0.000 description 34
- 238000012360 testing method Methods 0.000 description 30
- 238000002560 therapeutic procedure Methods 0.000 description 27
- 238000004458 analytical method Methods 0.000 description 20
- 238000003384 imaging method Methods 0.000 description 20
- 238000001514 detection method Methods 0.000 description 19
- 239000000090 biomarker Substances 0.000 description 14
- 230000008859 change Effects 0.000 description 14
- 238000012549 training Methods 0.000 description 14
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 13
- 239000002131 composite material Substances 0.000 description 13
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 description 12
- 230000000750 progressive effect Effects 0.000 description 11
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 11
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 238000010200 validation analysis Methods 0.000 description 9
- 229910052688 Gadolinium Inorganic materials 0.000 description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 238000013145 classification model Methods 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- 238000011979 disease modifying therapy Methods 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 238000009825 accumulation Methods 0.000 description 6
- 238000013528 artificial neural network Methods 0.000 description 6
- 238000004422 calculation algorithm Methods 0.000 description 6
- 230000005415 magnetization Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 210000001642 activated microglia Anatomy 0.000 description 5
- 208000038016 acute inflammation Diseases 0.000 description 5
- 230000006022 acute inflammation Effects 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000001363 autoimmune Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000000451 tissue damage Effects 0.000 description 5
- 231100000827 tissue damage Toxicity 0.000 description 5
- 210000004885 white matter Anatomy 0.000 description 5
- 208000024806 Brain atrophy Diseases 0.000 description 4
- 208000016192 Demyelinating disease Diseases 0.000 description 4
- 206010061818 Disease progression Diseases 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000013527 convolutional neural network Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000002598 diffusion tensor imaging Methods 0.000 description 4
- 230000005750 disease progression Effects 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 206010051290 Central nervous system lesion Diseases 0.000 description 3
- 206010012305 Demyelination Diseases 0.000 description 3
- 230000003376 axonal effect Effects 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000009266 disease activity Effects 0.000 description 3
- 230000004968 inflammatory condition Effects 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 102000006495 integrins Human genes 0.000 description 3
- 230000013016 learning Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007310 pathophysiology Effects 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 238000002790 cross-validation Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000013135 deep learning Methods 0.000 description 2
- JXSJBGJIGXNWCI-UHFFFAOYSA-N diethyl 2-[(dimethoxyphosphorothioyl)thio]succinate Chemical compound CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC JXSJBGJIGXNWCI-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 229950010704 opicinumab Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 229940079023 tysabri Drugs 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 206010069632 Bladder dysfunction Diseases 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 208000003164 Diplopia Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000014540 Functional gastrointestinal disease Diseases 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101001002508 Homo sapiens Immunoglobulin-binding protein 1 Proteins 0.000 description 1
- 102100021042 Immunoglobulin-binding protein 1 Human genes 0.000 description 1
- 238000012307 MRI technique Methods 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 102000008763 Neurofilament Proteins Human genes 0.000 description 1
- 108010088373 Neurofilament Proteins Proteins 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013473 artificial intelligence Methods 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000007844 axonal damage Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 201000007637 bowel dysfunction Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000007635 classification algorithm Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000002597 diffusion-weighted imaging Methods 0.000 description 1
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 description 1
- 229960004419 dimethyl fumarate Drugs 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 238000010234 longitudinal analysis Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 208000018731 motor weakness Diseases 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000007557 neuronal destruction Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 238000007637 random forest analysis Methods 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012706 support-vector machine Methods 0.000 description 1
- 230000007474 system interaction Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 230000008403 visual deficit Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163174399P | 2021-04-13 | 2021-04-13 | |
| FR2103793 | 2021-04-13 | ||
| US202263320655P | 2022-03-16 | 2022-03-16 | |
| PCT/US2022/024450 WO2022221297A1 (en) | 2021-04-13 | 2022-04-12 | Methods for classification of lesions and for predicting lesion development |
| PCT/US2022/024694 WO2022221458A1 (en) | 2021-04-13 | 2022-04-13 | Compositions and methods for treating chronic active white matter lesions / radiologically isolated syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP4323407A1 true EP4323407A1 (de) | 2024-02-21 |
Family
ID=81851070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP22726324.1A Pending EP4323407A1 (de) | 2021-04-13 | 2022-04-13 | Zusammensetzungen und verfahren zur behandlung von chronischen aktiven läsionen von weissem material / radiologisch isoliertem syndrom |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP4323407A1 (de) |
| JP (1) | JP2024513974A (de) |
| AU (1) | AU2022259605A1 (de) |
| CA (1) | CA3215371A1 (de) |
| WO (1) | WO2022221458A1 (de) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0307975A (pt) | 2002-02-25 | 2005-01-11 | Elan Pharm Inc | Métodos para reduzir cronicamente a inflamação patológica em um paciente e para determinar a eficácia de um regime de administração crÈnica para tratar inflamação patológica em um indivìduo, composição e terapia combinada para tratamento crÈnico de inflamação patológica em um paciente e uso de um inibidor de alfa-4-integrina |
| WO2008157356A2 (en) | 2007-06-14 | 2008-12-24 | Biogen Idec Ma Inc. | Antibody formulations |
| CN103635803A (zh) | 2011-05-31 | 2014-03-12 | 比奥根艾迪克Ma公司 | 评估进行性多灶性白质脑病风险的方法 |
| EP3004334A4 (de) | 2013-05-28 | 2016-12-21 | Biogen Ma Inc | Verfahren zur beurteilung eines pml-risikos |
-
2022
- 2022-04-13 CA CA3215371A patent/CA3215371A1/en active Pending
- 2022-04-13 WO PCT/US2022/024694 patent/WO2022221458A1/en active Application Filing
- 2022-04-13 EP EP22726324.1A patent/EP4323407A1/de active Pending
- 2022-04-13 AU AU2022259605A patent/AU2022259605A1/en active Pending
- 2022-04-13 JP JP2023562701A patent/JP2024513974A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024513974A (ja) | 2024-03-27 |
| WO2022221458A1 (en) | 2022-10-20 |
| CA3215371A1 (en) | 2022-10-20 |
| AU2022259605A1 (en) | 2023-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rahmanzadeh et al. | Myelin and axon pathology in multiple sclerosis assessed by myelin water and multi-shell diffusion imaging | |
| Amoroso et al. | Complex networks reveal early MRI markers of Parkinson’s disease | |
| Dickerson et al. | Biomarker-based prediction of progression in MCI: comparison of AD signature and hippocampal volume with spinal fluid amyloid-β and tau | |
| Wang et al. | Quantification of white matter cellularity and damage in preclinical and early symptomatic Alzheimer's disease | |
| Pustina et al. | Predicting the laterality of temporal lobe epilepsy from PET, MRI, and DTI: a multimodal study | |
| Zhang et al. | Characterization of white matter changes along fibers by automated fiber quantification in the early stages of Alzheimer's disease | |
| Del Sole et al. | Magnetic resonance imaging and positron emission tomography in the diagnosis of neurodegenerative dementias | |
| Goldsmith et al. | Penalized functional regression analysis of white-matter tract profiles in multiple sclerosis | |
| Mashayekhi et al. | Radiomic features of the pancreas on CT imaging accurately differentiate functional abdominal pain, recurrent acute pancreatitis, and chronic pancreatitis | |
| Calvi et al. | Association of slowly expanding lesions on MRI with disability in people with secondary progressive multiple sclerosis | |
| Deng et al. | Tractography-based classification in distinguishing patients with first-episode schizophrenia from healthy individuals | |
| Li et al. | Radiomics analysis of magnetic resonance imaging facilitates the identification of preclinical Alzheimer’s disease: an exploratory study | |
| Marcille et al. | Disease correlates of rim lesions on quantitative susceptibility mapping in multiple sclerosis | |
| Dadar et al. | Beware of white matter hyperintensities causing systematic errors in FreeSurfer gray matter segmentations! | |
| Rabasté et al. | Diagnostic value of bright spotty lesions on MRI after a first episode of acute myelopathy | |
| Vasta et al. | Hippocampal subfield atrophies in converted and not-converted mild cognitive impairments patients by a Markov random fields algorithm | |
| Lou et al. | Fully automated detection of paramagnetic rims in multiple sclerosis lesions on 3T susceptibility-based MR imaging | |
| Hamzaoui et al. | Positron Emission Tomography with [18F]‐DPA‐714 Unveils a Smoldering Component in Most Multiple Sclerosis Lesions which Drives Disease Progression | |
| Ma et al. | Identifying mild cognitive impairment with random forest by integrating multiple MRI morphological metrics | |
| Liu et al. | Multi-parametric diffusion tensor imaging of the optic nerve for detection of dysthyroid optic neuropathy in patients with thyroid-associated ophthalmopathy | |
| Kaaouana et al. | Improved cerebral microbleeds detection using their magnetic signature on T2*-phase-contrast: a comparison study in a clinical setting | |
| Bagnato et al. | Imaging chronic active lesions in multiple sclerosis: a consensus statement | |
| Smigielski et al. | White matter microstructure and the clinical risk for psychosis: A diffusion tensor imaging study of individuals with basic symptoms and at ultra-high risk | |
| Chu et al. | Comparison of brain microstructure alterations on diffusion kurtosis imaging among Alzheimer’s disease, mild cognitive impairment, and cognitively normal individuals | |
| AU2022259605A1 (en) | Compositions and methods for treating chronic active white matter lesions / radiologically isolated syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20231110 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |